• Flanders Investment & Trade
  • Team Vesalius

Medical doctor Patrik De Haes is a Non-Executive Chairman of Oxurion (formerly known as ThromboGenics), a biopharmaceutical company that develops treatments to preserve vision in patients with rare eye diseases.

Patrik De Haes


Non-Executive Chairman
Gaston Geenslaan 1
3001 Leuven

Skilled in medical device development, management, life sciences, and medicine, De Haes has over 25 years of experience in the biotechnology industry.

Before Oxurion, he was head of Roche's Global Insulin Infusion Business and CEO of Disetronic Medical Systems in Minneapolis (US), a leading insulin pump treatment company. As CEO of Sandoz Pharma – now Novatoris – De Haes was involved in the global development and commercialization of the first biotech product.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?